BAC announces collaboration with Sanofi Pasteur

BAC ANNOUNCES COLLABORATION WITH SANOFI PASTEUR FOR VACCINE PURIFICATION

Naarden, The Netherlands, 07th May 2007 – BAC BV, the Bio Affinity Company, announced today that it has entered into an agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group. BAC’s CaptureSelect^{^®}customised affinity ligands have been selected by sanofi pasteur as they potentially offer high stability and specificity for process-scale purification of some of its vaccine products. Sanofi pasteur is one of the world’s largest companies dedicated to developing human vaccines.

ABOUT BAC

BAC BV – The Bio Affinity Company – offers a wide range of products and services for affinity purification of biological materials from complex media. The Company’s proprietary CaptureSelect^{^®}affinity ligands, based on Camelid single chain antibody fragments, have been proven to be suitable in a wide range of biological applications including Life Science Research, Biomanufacturing and Healthcare.

CaptureSelect^{^®} ligand technology is based on selection of single chain antibody fragments with desirable chromatographic characteristics including robustness, high specificity and flexibility. Suitable ligands are cloned and expressed in high-titers through an animal-free Saccharomyces cerevisiae-based process.

BAC BV was established in 1995 as a Unilever subsidiary. Currently the Company employs 28 people with an R&D laboratory facility in Vlaardingen and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the Netherlands. For more information about BAC, visit our website at www.bac.nl. For more information about CaptureSelect^{^®} products, visit our website at www.captureselect.com

« back to news